Back to search

France· FR:63300452

HEMGENIX 1 x 10 000 000 000 000 copies du génome/mL, solution à diluer pour perfusion

A etranacogene dezaparvovec product containing étranacogène dézaparvovec, registered in France by CSL BEHRING (ALLEMAGNE). The same ATC class is registered in 10 of our 19 countries.

ATC B02BD16

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedHEMGENIX 1 x 10 000 000 000 000 copie…ATCB02BD16REGISTER NO.FR:63300452PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Etranacogene dezaparvovec is registered in 10 of 19 countries.

Countries holding a registration under ATC B02BD16 (etranacogene dezaparvovec), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Etranacogene dezaparvovec · ATC B02BD16

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ÉTRANACOGÈNE DÉZAPARVOVEC
Manufacturer
CSL BEHRING (ALLEMAGNE)
Country
France (FR)
ATC code
B02BD16
ATC class
Etranacogene dezaparvovec
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955094265
    flacon(s) en verre de 10 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0b893dd1-2cbf-4f93-9a89-7df3ff390008
GET /v1/drugs/0b893dd1-2cbf-4f93-9a89-7df3ff390008?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "63300452",
  "date_amm": "2023-02-20",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/22/1715",
  "substance": "ÉTRANACOGÈNE DÉZAPARVOVEC",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about etranacogene dezaparvovec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.